TAC-302 therapy seizes bladder cure market lead in China

This comes as the population ages and chronic conditions rise.

The TAC-302 therapy is anticipated to capture the highest market for the underactive bladder syndrome (UAB) in China and seven other markets (7MM) by 2034, according to DelveInsight.

TAC-302 is manufactured by Otsuka Holdings, and it is expected to be launched along with ZG-802 by Zeria Pharmaceutical and SFG-02 by SFG Sciences, it added.

The research also said that emerging UAB drugs, an aging global population, and rising prevalence of neurogenic and chronic conditions affecting bladder function will drive growth for the UAB syndrome market.  

Meanwhile, the firm estimated that the total diagnosed cases of a segmented UAB case, Lower Urinary Tract Symptoms (LUTS), in China and 7MM stood at approximately 67 million in 2024.

UAB is a clinical condition characterised by reduced bladder muscle contractility, resulting in prolonged or incomplete bladder emptying.  

From 2020 to 2034, DelveInsights projected that the UAB market will gain a 22.1% Compound Annual Growth Rate (CAGR) over the forecast period.

The forecast covered China, Japan, Germany, France, Italy, Spain, the United Kingdom, and the United States.

The market size stood at $107m in 2024.